![[10]-Shogaol](https://file.medchemexpress.com/product_pic/hy-n2434.gif "Click to View [10]-Shogaol Product Detail")
Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
40 Results for "
Docetaxel
" in MedChemExpress (MCE) Product Catalog:
Products (40)
40 Results for "Docetaxel" in MCE Product Catalog:
183
183
183 Publications Verification
Cat. No.: HY-B0011A
CAS No.: 148408-66-6
Synonyms: RP-56976 Trihydrate
Research Areas:
Docetaxel Trihydrate (RP-56976 Trihydrate) is an orally active tubulin stabilizer with antitumor activity. Docetaxel Trihydrate is a P-glycoprotein substrate and is metabolized by CYP3A to inactive products. Docetaxel Trihydrate binds tubulin, promotes tubulin polymerization, and inhibits microtubule depolymerization. Docetaxel Trihydrate induces aberrant mitosis followed by necrotic-like cell death at low concentrations, and induces G2/M mitotic arrest and drives apoptosis at high concentrations. Docetaxel Trihydrate induces renal injury/renal alterations, sex-dependent granule toxicity/uptake, low cardiac delivery, and decreased hepatic SOD/increased catalase/hepatotoxicity. Docetaxel Trihydrate can be used in cancer-related research .
12
Target:
Research Areas:
Flutamide is an Androgen Receptor antagonist with Ki=55 nM. Flutamide inhibits prostate cancer progression and has synergistic effects with Docetaxel (HY-B0011). Flutamide also has the potential to protect against hyperthermia-induced multiple organ dysfunction syndrome .
5
5 Cited Publications
Cat. No.: HY-N2434
CAS No.: 36752-54-2
Category:
Zingiber officinale Roscoe Monophenols Zingiberaceae Extract Phenols Plants Disease Research Fields Cancer
Target:
2
Target:
Research Areas:
10-Acetyl docetaxel (PNU-101383) is an analog of Docetaxel (HY-B0011), with anticancer activity. 10-Acetyl docetaxel is a microtubule disassembly inhibitor, with antimitotic activity .
2
2 Cited Publications
DUPA(OtBu)-OH is a DUPA precursor. DUPA is used as the targeting moiety to actively deliver Docetaxel (DTX) for treatment of Prostate-Specific Membrane Antigen (PSMA) expressing prostate cancer.
1
1 Cited Publications
Target:
Research Areas:
ALDH3A1-IN-1 (Compound 18) is a potent inhibitor of ALDH3A1 with an IC50 of 1.61 μM. ALDH3A1-IN-1 is more potent than DEAB against patient-derived primary prostate tumor epithelial cells, as single agents or in combination research with docetaxel .
1
1 Cited Publications
Target:
Research Areas:
PROTAC CYP1B1 degrader-1 is a CYP1B1 PROTAC degrader with a human IC50 of 95.1 nM. PROTAC CYP1B1 degrader-1 induces concentration-dependent CYP1B1 degradation. PROTAC CYP1B1 degrader-1 can be used for the research of CYP1B1-mediated Docetaxel (HY-B0011)-resistant prostate cancer .
Synonyms: HL-085
Tunlametinib is a highly selective, orally active MEK1/2 inhibitor (IC50=1.9 nM, MEK1). Tunlametinib blocks the RAS-RAF-MEK-ERK signaling pathway, arrests tumor cell cycle and promotes apoptosis. Tunlametinib potently inhibits the proliferation of RAS/RAF mutant cancer cells (such as BRAF V600E, KRAS G12C mutant cells). Tunlametinib shows synergistic anti-tumor effects with BRAF/KRASG12C/SHP2 inhibitors, Docetaxel (HY-B0011). Tunlametinib can be used to study targeted therapy for RAS/RAF mutation-driven malignancies (such as melanoma, colorectal cancer, and non-small cell lung cancer) .
Cat. No.: HY-B0011S
CAS No.: 940867-25-4
Synonyms: RP-56976-d9
Research Areas:
Docetaxel-d9 (RP-56976-d9) is the deuterated-labeled Docetaxel (HY-B0011). Docetaxel (RP-56976) is an orally active tubulin stabilizer with antitumor activity. Docetaxel is a P-glycoprotein substrate and is metabolized by CYP3A to inactive products. Docetaxel binds tubulin, promotes tubulin polymerization, and inhibits microtubule depolymerization. Docetaxel induces aberrant mitosis followed by necrotic-like cell death at low concentrations, and induces G2/M mitotic arrest and drives apoptosis at high concentrations. Docetaxel induces renal injury/renal alterations, sex-dependent granule toxicity/uptake, low cardiac delivery, and decreased hepatic SOD/increased catalase/hepatotoxicity. Docetaxel can be used in cancer-related research .
Cat. No.: HY-176835
CAS No.: 1424353-63-8
Target:
Research Areas:
PNR-3-80 is an endonuclease G (ENDOG) inhibitor with an IC50 of 0.67 μM. As a non-competitive binder to the ENDOG-substrate complex, PNR-3-80 specifically inhibits the endonuclease activity of ENDOG. PNR-3-80 reduces cell death induced by Cisplatin (HY-17394) and Docetaxel (HY-B0011), and inhibits DNA damage and autophagy (autophagy) induced by Etoposide (HY-13629). PNR-3-80 can be used in studies related to cell injury .
Cat. No.: HY-B0011R
CAS No.: 114977-28-5
Synonyms: RP-56976 (Standard)
Category:
Synonyms: SU093
NSC756093 (SU093) is a GBP1:PIM1 interaction inhibitor. NSC756093 binds to GBP1-PIM1 with a Kd of 38 nM. NSC756093 suppresses proliferation, reduces migration, induces G1 phase cell-cycle arrest, and increases apoptotic cell death in ovarian cancer cells. NSC756093 reduces cellular proteasomal activity, induces accumulation of ubiquitinated proteins, and restrains tumor progression and lung metastasis in murine ovarian cancer xenograft models. NSC756093 increases sensitivity of prostate cancer cells to Docetaxel (HY-B0011) and sensitizes GBP1-overexpressing ovarian cancer cells to Paclitaxel (HY-B0015). NSC756093 can be used for the research of prostate cancer and ovarian cancer .
LQZ-7F, a survivin dimerization inhibitor, induces spontaneous apoptosis and synergizes with Docetaxel in prostate cancer cells. LQZ-7F dose-dependently inhibits survival of both PC-3 and C4-2 cells with IC50s of 2.99 and 2.47 µM, respectively .
Cat. No.: HY-16674
CAS No.: 167074-97-7
Synonyms: Docetaxel Impurity 1
Target:
Research Areas:
10-Oxo Docetaxel (Docetaxel Impurity 1) is a novel taxoid having remarkable anti-tumor properties and a Docetaxel intermediate.
Cat. No.: HY-16676
CAS No.: 153381-68-1
Synonyms: 4-epi-Docetaxel; 7-EpiDocetaxel; 7-Epitaxotere
Target:
Research Areas:
7-Epi-docetaxel (4-epi-Docetaxel; 7-Epidocetaxel; 7-Epitaxotere) is the major C7 epimeric impurity/in vivo metabolite of Docetaxel (HY-B0011). 7-Epi-docetaxel acts as a potent allosteric activator of rhCYP1B1. 7-Epi-docetaxel exhibits certain cell line-specific anti-migratory activity . 7-Epi-docetaxel can be used in research related to melanoma and lung adenocarcinoma .
Target:
Research Areas:
CYP1B1-IN-7 (compound 2a) is a selective inhibitor of CYP1B1 (IC50: 75 nM). CYP1B1-IN-7 also reverses resistance (IC50: 29 μM) and exhibits cytotoxicity in the CYP1B1-overexpressing MCF-7 cell line that is resistant to Docetaxel (HY-B0011) .
Cat. No.: HY-W653942
Synonyms: RP-56976-d5
Research Areas:
Docetaxel-d5 (RP-56976-d5) is the deuterated-labeled Docetaxel (HY-B0011). Docetaxel (RP-56976) is an orally active tubulin stabilizer with antitumor activity. Docetaxel is a P-glycoprotein substrate and is metabolized by CYP3A to inactive products. Docetaxel binds tubulin, promotes tubulin polymerization, and inhibits microtubule depolymerization. Docetaxel induces aberrant mitosis followed by necrotic-like cell death at low concentrations, and induces G2/M mitotic arrest and drives apoptosis at high concentrations. Docetaxel induces renal injury/renal alterations, sex-dependent granule toxicity/uptake, low cardiac delivery, and decreased hepatic SOD/increased catalase/hepatotoxicity. Docetaxel can be used in cancer-related research .
Cat. No.: HY-B0011AS
Synonyms: RP-56976-d5 trihydrate
Research Areas:
Docetaxel-d5 trihydrate (RP-56976-d5 trihydrate) is the deuterated-labeled Docetaxel trihydrate (HY-B0011A). Docetaxel Trihydrate (RP-56976 Trihydrate) is an orally active tubulin stabilizer with antitumor activity. Docetaxel Trihydrate is a P-glycoprotein substrate and is metabolized by CYP3A to inactive products. Docetaxel Trihydrate binds tubulin, promotes tubulin polymerization, and inhibits microtubule depolymerization. Docetaxel Trihydrate induces aberrant mitosis followed by necrotic-like cell death at low concentrations, and induces G2/M mitotic arrest and drives apoptosis at high concentrations. Docetaxel Trihydrate induces renal injury/renal alterations, sex-dependent granule toxicity/uptake, low cardiac delivery, and decreased hepatic SOD/increased catalase/hepatotoxicity. Docetaxel Trihydrate can be used in cancer-related research .
- 1
- 2
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
